Champignon Brands

CSE: SHRM | OTC: SHRMF | FWB: 496

Champignon Brands is a publicly-traded, research-driven company active in the formulation and production of a variety of psychedelic medicines and products.

The Company has been subject to a Continuous Disclosure Review by the BC Securities Commission, and as such SHRM shares are currently under a Cease Trade Order.

[mstock id="3014"]

[mstock id="3015"]

Exclusive Interview

We spoke with Dr. Roger McIntyre, CEO of Champignon Brands, about his immediate and future plans for the company…

Latest News

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

May 3, 2021

Champignon Brands Announces Revocation of Cease Trade Orders

April 22, 2021

Champignon Brands Announces Filing of Listing Statement

March 26, 2021

Champignon Brands to Restate Financial Statements and MD&A has Prepared CSE Listing Statement

February 17, 2021

Dr. Roger McIntyre Announces Changes to the Board of Champignon Brands Inc.

February 4, 2021

Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

January 25, 2021

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.

The VA, Psychedelics, and the Future of Mental Health: A Conversation with Shereef Elnahal, Former VA Under Secretary for HealthApril 14, 2025
Dr. Shereef Elnahal, former VA Under Secretary for health, discusses how he came to champion psychedelic research within the VA, the promising data in conditions like PTSD and substance use disorders, and the institutional groundwork needed to support the potential roll-out of these therapies at scale. He also shares his opinions on the balancing act between medicalisation and advocacy, and what a coordinated federal approach to psychedelics might, or should, look like.
Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-UpsApril 11, 2025
‘Everything’s On the Table’: VA Secretary Signals Openness to Psychedelics, But Concrete Plans Lacking • Drug Developers Caught Between Tariff Talk, Agency Shake-Ups, and Market Mayhem • Multi-Lab Preprint Study Challenges Replicability of Psilocybin’s Persistent Effects in Mice • Kwan Lab Links 5-HT2A Receptors and Pyramidal Tract to Psilocybin’s Lasting Effects in Mice • FDA Clears Nation’s First Whole-Mushroom Psilocybin Study • Terran vs. Compass Lawsuit Moves Forward as Court Rejects Dismissal • and more...
Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape 2025 LandscapeApril 9, 2025
As New Mexico’s Medical Psilocybin Act Passes, Questions of Access, Provider Risk, and Industry Influence Loom • Arizona’s Oregon-Style Psilocybin Services Bill Gutted and Replaced by Compass Pathways’ Crystalline Polymorph Psilocybin Rescheduling Trigger Law • A Mixed Bag for Compass’ Other Trigger Law Bills • Idaho HJR 4 Passes, Preventing Voters from Legalising Psychoactive Drugs via Ballot Initiatives • Arizona Bill Carving Out $5M for Ibogaine Research Passes House, Working Way through Senate
BREAKING: New Mexico Passes Nation’s First Legislature-Driven Psilocybin Access ActApril 8, 2025
Yesterday, New Mexico Governor Michelle Lujan Grisham (D) signed SB 219, the Medical Psilocybin Act, which will establish the third state-legal psilocybin access system in the US. In simple terms, the Act creates a framework through which patients with qualifying conditions can access and use non-synthetic psilocybin through consultation with a licensed healthcare provider.
March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S. as Nearly 30 States Deliberate ReformsApril 7, 2025
With a half-dozen new states joining 2025's psychedelic policy reform push, there are now nearly thirty state legislatures mulling such proposals. Here, Noah Smith and Josh Hardman run through them state-by-state, bill-by-bill.

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.